News - Bayer, Licensing


Current filters:


Popular Filters

Bayer pays upfront $50 million for Orion’s prostate cancer candidate ODM-201

Bayer pays upfront $50 million for Orion’s prostate cancer candidate ODM-201


Finland-based drugmaker Orion Corp has entered into a global partnership with German pharma major Bayer…

BayerGlobalLicensingODM-201OncologyOrion CorpPharmaceuticalResearch

KYTHERA regains rights to ATX-101 outside USA and Canada from Bayer

KYTHERA regains rights to ATX-101 outside USA and Canada from Bayer


US biotech firm KYTHERA Biopharmaceuticals says it has re-acquired all rights outside of the USA and…

ATX-101BayerDermatologicalsKYTHERA BiopharmaceuticalsLicensingNorth AmericaPharmaceutical

X-Chem licenses drug discovery program to Bayer

X-Chem licenses drug discovery program to Bayer


X-Chem Inc, a privately held US biotechnology company focused on applying its innovative drug discovery…


Regeneron and Bayer expand deal to develop new option for wet-AMD

Regeneron and Bayer expand deal to develop new option for wet-AMD


US biotech firm Regeneron Pharmaceuticals said yesterday that it has expanded its accord with German…


Bayer enters a further academic collaboration on innovative cancer therapies


In a further collaboration with academia, German pharma and chemical major Bayer (BAYN: DE) has entered…


Bayer inks multi-million dollar cancer immunotherapy deal


Germany's largest pharma company Bayer (BAYN: DE) has entered into a new oncology collaboration and license…


Paladin Labs acquires Binotal rights in Latin America from Bayer


Canadian specialty pharma firm Paladin Labs (TSX: PLB) has signed an agreement with German drug major…

Antibiotics and Infectious diseasesBayerBinotalLicensingPaladin LabsPharmaceuticalSouth America

Bayer to spend up to $520 million on antibody drug conjugate deal with Seattle Genetics


US biotech firm Seattle Genetics (Nasdaq: SGEN) says it has entered into a new antibody-drug conjugate…

BayerBiotechnologyLicensingOncologyPharmaceuticalSeattle Genetics

News briefs from Bayer, AstraZeneca and Valeant/Galderma


German drug major Bayer (BAYN: DE) and partner Regeneron (Nasdaq: REGN) submitted a marketing application…

AstraZenecaBayerEuropeEyleaFaslodexGaldermaLicensingNorth AmericaOncologyOphthalmicsPerlanePharmaceuticalRegulationRestylaneValeant Pharmaceuticals

Bayer inks up to 592 million-euro endometriosis deal with Evotec


Drug major Bayer (BAYN: DE) and fellow German company Evotec (EVT: TecDAX) have entered into a five-year,…

BayerEvotecLicensingPharmaceuticalWomen's Health

Nordic Group gets ex-US right to Trasylol from Bayer


Privately-held Netherlands-based Nordic Group has reached an agreement with Germany's Bayer (BAYN: DE)…

BayerCardio-vascularLicensingNordic GroupPharmaceuticalTrasylol

KYTHERA Biopharma gets $33.3 million in payments from Bayer


Privately-held US biotech firm KYTHERA Biopharmaceuticals says it has received a $15.8 million payment…

BayerBiotechnologyFinancialKYTHERA BiopharmaceuticalsLicensingPharmaceuticalResearch

Roche returns rights to TB-403 to ThromboGenics and BioInvent, who abandon TB-402 development


Belgium-based biopharma company ThromboGenics NV (Euronext Brussels: THR) and co-development partner…


Milestone payment for Ardea from Bayer, which executes license with Dyax


AstraZeneca (The Pharma Letter April 23), said yesterday that it has earned a $7.5 million milestone…

Ardea BiosciencesBAY 86-9766BayerDyax CorpFinancialLicensingOncologyPharmaceuticalResearch

Santen to co-promote Bayer and Regeneron's Eylea in Japan


German drug major Bayer's (BAYN: DE) Japanese subsidiary, Bayer Yakuhin, and Santen Pharmaceutical (TYO:…

Asia-PacificBayerEyleaLicensingMarkets & MarketingOphthalmicsPharmaceuticalRegeneronSanten Pharmaceuticals

Algeta takes up option to co-promote Alpharadin in the USA


Norwegian cancer therapeutics developer Algeta ASA (OSE: ALGETA) says that it has exercised its option…

AlgetaAlpharadinBayerLicensingMarkets & MarketingOncologyPharmaceutical

Bayer settles with Onyx over Nexavar and regorafenib with $160 million payment


US drugmaker Onyx Pharmaceuticals (Nasdaq: ONXX) and German pharma major Bayer HealthCare, a unit of…

BayerLegalLicensingNexavarOncologyOnyx PharmaceuticalsPharmaceuticalregorafenib

Back to top